Actuate Therapeutics Inc (ACTU)
NASDAQ: ACTU
· Real-Time Price · USD
7.12
0.07 (0.99%)
At close: Jun 24, 2025, 9:57 AM
0.99% (1D)
| Bid | 6.99 |
| Market Cap | 139.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.31M |
| EPS (ttm) | -3.15 |
| PE Ratio (ttm) | -2.26 |
| Forward PE | -5.61 |
| Analyst | Buy |
| Ask | 7.33 |
| Volume | 34,819 |
| Avg. Volume (20D) | 67,912 |
| Open | 7.29 |
| Previous Close | 7.05 |
| Day's Range | 7.08 - 7.31 |
| 52-Week Range | 5.51 - 11.99 |
| Beta | 1.69 |
About ACTU
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACTU
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACTU stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-11.01%
Actuate Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
1 month ago
-6.88%
ACTU stock has given up its prior gain. Actuate Therapeutics shares were trading higher after the company announced elraglusib combined with GnP met its primary endpoint in its ongoing Phase 2 trial.